THE FUTURE, - Solvay
THE FUTURE, - Solvay
THE FUTURE, - Solvay
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
209749 209799<br />
MEDEXIS: MANAGING AND INTERLINKING<br />
INFORMATION USED BY OCCUPATIONAL<br />
PHYSICIANS AND HYGIENISTS ON<br />
WORKPLACE RISKS<br />
Medexis: a worldwide<br />
observatory for better health<br />
at work<br />
<strong>THE</strong> PROJECT. Medexis is a database which<br />
exploits individual medical data by associating<br />
them with information on the exposure of <strong>Solvay</strong><br />
personnel to chemicals and other hazardous<br />
products. Medexis has been developed on SAP<br />
and is fully integrated with other SAP modules,<br />
which is a fi rst. This is a worldwide project,<br />
designed to ensure a fl ow of complete,<br />
standardized and reliable data in areas that were<br />
previously separate: scientifi c, toxicological and<br />
regulatory information on substances, noise and<br />
vibration, exposure levels of each employee, and<br />
individual medical follow-up.<br />
The system will make it possible to establish new<br />
correlations between working conditions and<br />
health, to identify as yet unknown health issues<br />
and to take decisions more effectively to improve<br />
the situation.<br />
The system is also a management tool designed<br />
to manage all hygiene and occupational medicine<br />
activities in the <strong>Solvay</strong> group at both local and<br />
corporate level (follow-up of actions and results,<br />
scorecard and indicators, internal benchmarking,<br />
costs of services, etc.). Medexis will also make it<br />
possible to share best practices and best<br />
prevention strategies worldwide. The deployment<br />
of this system is one of the Group’s 25 key<br />
sustainable development objectives - the goal<br />
being to implement it at 80% of Group sites by<br />
2012.<br />
CC HSE<br />
> Christiane Baleux; Willy Asnong;<br />
Nathalie Berne; Jean-Paul Capelle; Pierre Coërs;<br />
Stéphanie Gauzente; Philippe Hannequart;<br />
Aline Huge; Thomas Paschek; Brigitte Sion;<br />
Jack Smit; Paul Vanhemelryck.<br />
CDM PROJECT THROUGH RECOVERY OF<br />
SF6 FROM GAS-INSULATED EQUIPMENT IN<br />
TESTING FACILITIES<br />
SF6 contributes to<br />
the Kyoto objectives<br />
<strong>THE</strong> PROJECT. The CDM (Clean Development<br />
Mechanism) project benefi ts from the fl exibility of<br />
the Kyoto Protocol which states that developing<br />
countries such as Korea may contribute to the<br />
reduction of greenhouse gas emissions by<br />
participating in international ‘emission trading’<br />
under United Nations supervision.<br />
Specifi cally, the SF6 (sulfur hexafl uoride) gas<br />
which serves as insulation in electrical systems<br />
tested at KERI (Korea Electrotechnology Research<br />
Institute) is recovered, transported, processed and<br />
recycled by <strong>Solvay</strong> Fluor instead of being<br />
discharged to the atmosphere.<br />
This partnership project is at the development<br />
stage. The methodology was approved in March<br />
2009 and it should be validated in August 2009,<br />
verifi ed in 2010, and implemented for the fi rst<br />
time in 2011.<br />
It will provide additional income to <strong>Solvay</strong>, along<br />
with energy and raw materials savings (up to<br />
10 tons of SF6 per year) and contribute to the<br />
Group’s reputation in Korea, with an image as a<br />
leader in environmental protection and<br />
sustainable development.<br />
SBU FLUOR<br />
> Seung-Bong Choi; Dae-Jun Han; Ho-Jin Jeon;<br />
Hans-Jürgen Korte.<br />
209824<br />
<strong>THE</strong> SOLVAY ANIMAL CARE AND USE<br />
COMMITTEE: AN INDEPENDENT OVERSIGHT<br />
GROUP OF EXPERTS FROM OUTSIDE AND<br />
INSIDE <strong>THE</strong> COMPANY<br />
A better life for animals<br />
<strong>THE</strong> PROJECT. To be sustainable, all <strong>Solvay</strong><br />
activities must be justifi able and acceptable to<br />
society as well as to the people that work for the<br />
Group. The Executive Committee has adopted an<br />
animal policy which includes the creation of an<br />
independent oversight committee, the <strong>Solvay</strong><br />
group Animal Care and Use Committee or SACUC.<br />
Independence is important when ethical and<br />
moral considerations might potentially confl ict<br />
with business goals. With an equal numbers of<br />
external and internal experts with specialist<br />
knowledge of animal experimentation, animal<br />
alternatives and animal ethics, the committee<br />
gives advice to <strong>Solvay</strong>’s most senior managers on<br />
the care, use and protection of animals and on<br />
replacement, reduction and refi nement (the 3 Rs)<br />
in the use of all animals.<br />
PHARMACEUTICALS SECTOR<br />
> Roger Bickerstaffe; Pierre Coërs;<br />
Jacques de Gerlache; Bruno Schmit;<br />
Susanne Thun-Battersby.<br />
<strong>Solvay</strong> <strong>Solvay</strong> live live - JUILLET - JULY 2009 - 51